



NDA 10-104/S-022

Merck & Co., Inc.
Attention: Virginia G. Snyder
Manager, Regulatory Affairs
Sumneytown Pike
P.O. Box 4, BLA-20
West Point, PA 19486

Dear Ms. Snyder:

Please refer to your supplemental new drug application dated August 26, 2003, received August 28, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for MEPHYTON[®] (phytonadione) Tablets.

This supplemental new drug application provides for a new subsection titled *Geriatric Use* under the **PRECAUTIONS** section to include information regarding the use of phytonadione in the elderly.

We completed our review of this application and it is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the submitted labeling (package insert submitted August 26, 2003).

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 10-104/S-022." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Susan Daugherty, Consumer Safety Officer, at (301) 827-7456.

Sincerely,

{See appended electronic signature page}

Robert L. Justice, M.D., M.S.

Director

Division of Gastrointestinal
and Coagulation Drug Products

Office of Drug Evaluation III

Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Joyce Korvick
2/9/04 12:29:39 PM
for Dr. Robert Justice